186 related articles for article (PubMed ID: 12711116)
21. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH
Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876
[TBL] [Abstract][Full Text] [Related]
23. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of DNA double strand break repair and chromosome aberration formation.
Iliakis G; Wang H; Perrault AR; Boecker W; Rosidi B; Windhofer F; Wu W; Guan J; Terzoudi G; Pantelias G
Cytogenet Genome Res; 2004; 104(1-4):14-20. PubMed ID: 15162010
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure.
Soubeyrand S; Pope L; Haché RJ
Mol Oncol; 2010 Feb; 4(1):38-51. PubMed ID: 19858003
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
27. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Dingemans AC; van Ark-Otte J; Span S; Scagliotti GV; van der Valk P; Postmus PE; Giaccone G
Lung Cancer; 2001 May; 32(2):117-28. PubMed ID: 11325482
[TBL] [Abstract][Full Text] [Related]
29. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
30. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
31. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
[TBL] [Abstract][Full Text] [Related]
32. Re: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
Liu WM; te Poele RH; Joel SP
J Natl Cancer Inst; 1998 Feb; 90(3):246-7. PubMed ID: 9462684
[No Abstract] [Full Text] [Related]
33. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Matsumoto Y; Kunishio K; Nagao S
J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
[TBL] [Abstract][Full Text] [Related]
34. DNA damage-dependent nuclear dynamics of the Mre11 complex.
Mirzoeva OK; Petrini JH
Mol Cell Biol; 2001 Jan; 21(1):281-8. PubMed ID: 11113202
[TBL] [Abstract][Full Text] [Related]
35. A nucleotide resolution map of Top2-linked DNA breaks in the yeast and human genome.
Gittens WH; Johnson DJ; Allison RM; Cooper TJ; Thomas H; Neale MJ
Nat Commun; 2019 Oct; 10(1):4846. PubMed ID: 31649282
[TBL] [Abstract][Full Text] [Related]
36. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Rossman J; Reddy V; Cantor A; Miley D; Robert F
Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
[TBL] [Abstract][Full Text] [Related]
38. FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1.
Xing Y; Wang ZH; Ma DH; Han Y
J Dig Dis; 2014 May; 15(5):246-59. PubMed ID: 24868599
[TBL] [Abstract][Full Text] [Related]
39. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
40. MRE11 function in response to topoisomerase poisons is independent of its function in double-strand break repair in Saccharomyces cerevisiae.
Hamilton NK; Maizels N
PLoS One; 2010 Oct; 5(10):e15387. PubMed ID: 21060845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
